48.67
0.31%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Sanofi ADR Borsa (SNY) Ultime notizie
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Zacks Investment Research
Could Novavax Become the Next Moderna?
The Motley Fool
Top Analyst Reports for Oracle, Bank of America & McDonald's
Zacks Investment Research
Quarterly Snapshot: Quick and Current Ratios for Sanofi ADR (SNY) – DWinneX - The Dwinnex
The Dwinnex
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks Investment Research
SNY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
The InvestChronicle
Pfizer: Best Trading Momentum Since 2021 And 6% Yield
Seeking Alpha
2024-05-15 | NYSE:TEVA | Press Release | Teva Pharmaceutical Industries ADR Representing One - Stockhouse Publishing
Stockhouse Publishing
Sanofi ADR: Is SNY Stock Worth Buying? – Stocks Register - Stocks Register
Stocks Register
Novavax Stock Just Tripled. Is It Too Late to Buy?
The Motley Fool
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
Zacks Investment Research
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Zacks Investment Research
Company News For May 13, 2024
Zacks Investment Research
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED)
Benzinga
Why Novavax Stock More Than Doubled Today
The Motley Fool
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
Benzinga
Novavax shares skyrocket after billion-dollar licensing deal with Sanofi - Proactive Investors UK
Proactive Investors UK
Novavax shares soar on license deal with Sanofi at lofty valuation - The Globe and Mail
The Globe and Mail
Novavax's share price surges after inking co-licensing deal with pharma giant - The Business Journals
The Business Journals
Novavax shares soar on license deal with Sanofi at lofty valuation - The Globe and Mail
The Globe and Mail
Sanofi's New Cancer Drug Could Help Deliver a Big Payday
The Motley Fool
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
Zacks Investment Research
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks Investment Research
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks Investment Research
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The Motley Fool
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks Investment Research
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks Investment Research
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks Investment Research
Sanofi (SNY) Q1 2024 Earnings Call Transcript
The Motley Fool
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks Investment Research
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Benzinga
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks Investment Research
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Zacks Investment Research
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Morningstar
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Benzinga
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
Seeking Alpha
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Benzinga
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Zacks Investment Research
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
Zacks Investment Research
Sanofi: My Top Pick In Big Pharma
Seeking Alpha
SNY: Top 3 Pharma Innovators to Watch Closely - StockNews.com
StockNews.com
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
Zacks Investment Research
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks Investment Research
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
Zacks Investment Research
Weekly Upgrades and Downgrades - InvestorPlace
InvestorPlace
Local CF startup raises one of the largest VC rounds in Mass. so far this year - Boston Business Journal - Boston Business Journal
Boston Business Journal
Beyond the Magnificent 7, These European Giants Keep Soaring Under the Radar
Investing.com
‘GRANOLAS’ vs. the Magnificent Seven: Which should you dig into now?
MarketWatch
Capitalizzazione:
|
Volume (24 ore):